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Abstract
Background: Despite the growing body of literature and putative links between the use of ergogenic nutritional
supplements, doping and illicit drugs, it remains unclear whether, in athletes’ minds, doping aligns with illicit
behaviour or with functional use of chemical or natural preparations. To date, no attempt has been made to
quantitatively explore athletes’ mental representation of doping in relation to illegality and functionality.
Methods: A convenience sample of student athletes from a large South-Eastern Australian university responded to
an on-line survey. Competitive athletes (n = 46) were grouped based on self-reported use as follows: i) none used
(30%), ii) supplement only (22%), iii) illicit only (26%) and iv) both supplements and illicit drug use (22%). Whereas
no athlete reported doping, data provided on projected supplement-, doping- and drug use by the four user
groups allowed evaluation of doping-related cognition in the context of self-reported supplement- and illicit drug
taking behaviour; and comparison between these substances.
Results: A significantly higher prevalence estimation was found for illicit drug use and a trend towards a biased
social projection emerged for supplement use. Doping estimates by user groups showed mixed results, suggesting
that doping had more in common with the ergogenic nutritional supplement domain than the illicit drug domain.
Conclusions: Assessing the behavioural domain to which doping belongs to in athletes’ mind would greatly
advance doping behaviour research toward prevention and intervention. Further investigation refining the
peculiarity of the mental representation of doping with a larger study sample, controlling for knowledge of doping
and other factors, is warranted.
Background
One of the key constraints in designing effective anti-
doping programs is the lack of conceptual clarity of the
psychological mechanisms that influence doping beha-
viour. For example, preventing doping use in sport on
the basis of fair play vs. cheating naturally lends to pre-
vention and intervention programs that focus on the
ethics of anti-doping and values, coupled with the con-
sequences of being caught - not necessarily limited to
sanctions but including dishonour, shame and guilt.
Other programs may emphasise the potential hazards
and detrimental health effects as consequences of dop-
ing use, which are omnipresent, independently from
doping testing and sanctioning. What is largely
unknown is what approach (if any) works as an effective
deterrent [1]. Studies have investigated factors such as
health [2], morality, sanctions if caught [3] and access
[4] without making an attempt to construct a mental
representation of doping in relation to morality and
functionality. Evidence based on self reports has also
been put forward suggesting a connection between pro-
hibited performance enhancing and illicit drug use
[5-10]. A potentially causal relationship between nutri-
tional supplement (NS) use and doping has been sug-
gested both theoretically [11] and empirically [12,13].
In the recent years, a number of athletes have talked
publicly about their reasons and motives for doping use,
contrasting perceived obligations and duty to perform
well with guilt and the shame of lying. Studies con-
ducted among professional athletes, particularly cyclists,
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any medium, provided the original work is properly cited.offer valuable insight into how athletes perceive doping;
and how this perception varies in different contexts
[14-19]. In addition to the fact that many athletes con-
sider doping as part of professional sport, most openly
talk about experimentation with non-prohibited sub-
stances such as over-the-counter painkillers and non-
steroidal anti-inflammatory drugs, caffeine and other
non-prohibited stimulants [15,16]. Nutritional supple-
ment use, which has been considered as a gateway to
doping by many [12-14,20] is common among emerging
and elite athletes [21-28] and has raised concerns on its
own account owing to potentially harmful interactions
from combined use and high dosage [29-32].
The question of whether doping behaviour has the
character of illicit substance use, ergogenic substance
use, neither or both has been recently raised in connec-
tion with anabolic steroids [33]. The ongoing debate is
around whether the use of prohibited ergogenic sub-
stances aligns with behaviours associated with illicit sub-
stance use (e.g. psychoactive controlled drugs) or with
nutritional (ergogenic) supplement use. Resolving which
behavioural domain doping belongs in athletes’ mind
provides valuable insight for primary prevention activity.
As doping has been categorised as an illicit (illegal)
activity, it follows illicit drug models. Thus, the current
anti-doping prevention follows typical demand control
models seen for illicit drug use that focus on health edu-
cation. It may be that the behaviour is functional with
regard to its performance enhancing qualities. There is
c u r r e n t l yl i t t l ei nt h ew a yo f ergogenic supplement pri-
mary prevention. Finally, doping may be an entirely new
class of drug use behaviour, requiring a new set of pri-
mary prevention activities to be developed. The present
research aims to inform which of these might be the
case.
This pilot study is part of a larger research pro-
gramme investigating social projection in various sam-
ples and context [34-37] and arose from some
unexpected, but potentially far-reaching observations.
The original aim of these studies was to investigate the
utility of the biased social projection (False Consensus)
a sap r o x ym e a s u r ef o rs u b s t a n c eu s e .F o l l o w i n gf r o m
the findings [34,35], this study aims to compare and
contrast social projection in different substance cate-
gories (i.e. supplements, illicit drugs and performance
enhancing drugs) among athletes to quantitatively
explore athletes’ mental representation of doping in
relation to illegality and functionality.
Previous results investigating social projection in per-
formance enhancing and illicit drug use suggest that
projected prevalence of doping and drug use was higher
among self-admitted users respectively but absent for
nutritional supplement use [34], and that this social pro-
jection was domain specific [35]. Domain specificity
refers to an observed phenomenon that admitted doping
use came with high estimations of doping use among
other athletes with illicit drug use remaining unaffected;
and conversely illicit drug users gave higher estimations
of illicit drug use among others with estimated doping
use remaining unaffected [35]. Although differentiating
between cause and effect between social projection and
behaviour in data from cross sectional research is
impossible, the relationship is clearly present in self-
reported data [34-37]. Interestingly, this phenomenon is
only observable within the cognitively controlled infor-
mation when athletes admitted the use of one or both
of these drugs [36,37].
The importance of the social project lies with the
question of whether an elevated and potentially dis-
torted social projection leads to a congruent behavioural
choice or resulted from it [38]. The fact that social pro-
jection aligns with self-reported behaviour but not
necessarily with actual behaviour is intriguing, but more
importantly it reveals something about athletes’ cogni-
tive processes relating to these substances. Thus, this
may be used to gain insight into athletes’ implicit men-
tal representation of these, often concomitantly used,
substances. Therefore by ‘mental representation’ we
refer to an inferred psychological construct of which the
athletes may be unaware. Congruently, the term ‘ath-
lete’sm i n d ’ refers to the way athletes may subcon-
sciously think about doping.
With the view of gaining some insight into athletes’
implicit mental representation, we focused on social
projection as an indirect indicator of mental representa-
tion of doping. Whilst recent evidence suggests that
social projection cannot be safely used as a proxy for
behavioural measures [36,37], declared social projections
tells us something important about how doping is posi-
tioned in people’s conscious mind. Descriptive norms
are individuals’ perceptions of how common a particular
behaviour is. These norms are likely to be affected by
some degree of projection (i.e. x% of athletes use dop-
ing). In particular, the projection may suffer from a
social bias coined the ‘False Consensus Effect’ (FCE)
[39] by which peoples’ perception of their environment
(including the behaviours of others) is distorted, thus
resulting in a higher estimation.
The FCE is a perceptual bias where people who
engage in particular behaviours tend to overestimate the
proportion of the population who also engage in that
behaviour. People who abstain either underestimate or
correctly estimate prevalence. For example, marijuana
users tend to overestimate the proportion of the popula-
tion who use marijuana, and non-users are more accu-
rate or underestimate [40,41]. A further characteristic is
that the FCE is domain specific as it works within rather
than across different categories or domains of behaviour
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enon, users of nutritional supplements should overesti-
mate doping and vice versa (the positive case).
Conversely if doping belongs to another domain, then
the estimates of doping would occur independently of
nutritional supplement use (the negative case). This sug-
gests the relatedness of doping with either illicit or ergo-
genic substance use behaviours can be determined by
emergent patterns of the FCE across behaviours.
In order to elucidate the peculiarities observed in the
supplement-doping-drug triangle, this paper aims to test
the domain specificity of doping relative to illicit sub-
stance and ergogenic nutritional supplement use via the
FCE to explore whether it is an illicit or functional phe-
nomenon. A proposed schema of mental representation
of doping is depicted in Figure 1. Table 1 summarises
the expected domain specific outcomes by user groups,
assuming mutually exclusive categories (i.e. a nutritional
supplement user is not a doping user or illicit drug user,
etc.). In reality (and in our sample), it is likely that ath-
letes use substances from two or even all three of these
substance categories, thus making mixed categories with
testable differences in their estimations of drug, doping
and NS use. We hypothesise that commonality may
emerge from the implicit mental representation. For
example, athletes construct doping as illicit drug use
and therefore athlete illicit drug users also overestimate
doping. The legality of the substances may have a con-
founding influence, but this would have to be the sub-
ject of a future study following articulation of the
concept offered here. A prediction in the NS use cate-
gory is dependent on whether we believe that the FCE
is purely retrospective justification, in which case, the
projected figure should show no difference for two rea-
sons: i) NS use is not a sensitive question and ii) we
assume domain specificity (i.e. NS use is independent of
doping and social drug use). However, if the FCE is,
indeed, a normative belief, and the gateway theory
stands, it would be logical to assume that NS users
might give a higher estimation of doping users com-
pared to their non-user counterpart. Although a similar
argument could be put forward for the doping - illicit
drug pair (i.e. use of one leads to the use of the other)
but previous results indicated that this is not the case
[35].
Method
Following ethics approval, an on-line survey collected
data from students attending a South-Eastern Australian
university. Every student of the student population of >
40,000 who logged into the website during the 4-week
period in 2009 received the link to the survey, with no
tracking option as imposed on the project by the institu-
tional ethics committee. This convenience sampling
method yielded 186 responses, of which n = 127 (86
usable) were athletes and n = 59 were from the general
student population (comparison group for selected ques-
tions). A number of respondents provided variably
incomplete data across the question set.
The athlete group (86 usable) was further restricted to
those in 3
rd grade sport or above (n = 46) imposed for
investigating the mental representation. This selection
criterion was based on the level of sport involvement.
Australian 3
rd grade sport represents a point at which
club sport begins to feed into professional or elite sport,
or serve as a transition after injury or is used to regain
form for professional or elite athletes. Students who
reported participating at 3
rd grade or above captures
student athletes who may experience the competitive
pressures of sport differently to those who participate in
recreational or social sport. Recruitment was via a link
on the top page of the administrative web site used by
students for enrolment, examination timetables and so
on. The on-line survey was part of a larger study on
responses to the use of different kinds of substances in
sporting contexts. Only the measures of relevance are
reported, namely: i) age, gender, sport and level of parti-
cipation; ii) questions on illicit drug use in the general
Figure 1 Proposed schema of the mental representation of doping (prohibited performance enhancing substances).
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supplement use in the general population and personal
use; and iv) questions on doping use in the athlete
population and personal use.
The dependent variables were estimated population
prevalence of nutritional supplement, illicit drug use
and doping. These substances were defined as follows:
‘Nutritional supplements’ are vitamins (e.g. vitamin A, B,
C, E, D, etc.), minerals (e.g. iron, zinc, calcium, magne-
sium, etc.) and non-vitamin non-mineral substances
including herbals and botanicals (e.g. creatine prepara-
tions, St John’s Worth, Ginco biloba, Echinacea, Guar-
ana, Ginseng, protein solutions, glucosamine, coenzyme
Q10, lecithin, melatonin, fish oil, shark cartilage, etc.).
‘Doping’ or ‘banned substances’ are those substances
that are prohibited by the World Anti-Doping Agency
or other governing body in training and/or competition.
‘Social drugs’ are psychoactive drugs (e.g. stimulants,
opiates, cannabis, cocaine, etc.) used for recreational
purposes rather than for work, medical or spiritual rea-
sons. Although caffeine, alcohol and tobacco are also
social drugs, are excluded from the definition in this
survey. These definitions we r ep r o v i d e da tt h es t a r to f
the questionnaire and used in this manuscript. The
terms ‘social drugs’ and ‘illicit drugs’; ‘doping’ and ‘pro-
hibited performance enhancing substances’ are used
interchangeably throughout the paper.
The FCE was gauged by asking respondents to make
an estimation of the level of fellow athletes using pro-
hibited performance enhancing substances, illicit drugs
and nutritional supplements independently asking ‘What
% of others in your sport has used a banned substance?’.
The responses were recorded on a percentage scale
where 0% means that nobody and 100% means that
everybody uses a substance.
In addition, athletes were asked about their beliefs
regarding the effectiveness and necessity of various per-
formance enhancing substances using the following
questions: i) ‘Do you believe that most people need sup-
plementation to balance their diet?’ (Yes/No/I don’t
know) and ii) ‘Do you believe that it is possible to win in
high level sport competitions without doping?’ (Yes/No/I
don’t know).
The FCE tests compared estimated lifetime prevalence
rates by personal use (independent variables with levels
“yes” and “no”). Domain specificity was assessed by
examining whether the FCE emerged by personal use
within and across substances. In operational terms,
domain specificity emerges from the absence of the FCE
when users of one substance (e.g. illicit drug users) esti-
mate the prevalence of another unaccepted drug (e.g.
doping). Estimations for substances with similar ergo-
genic effects to doping but with generally accepted use
(e.g. nutritional supplements) were expected to show no
difference between users and non-users.
One-way analysis of variance assessed differences
between groups with Tukey’s HSD post hoc test when
required. To test domain specificity, logistic regression
was used for the prediction of the probability of an
event (i.e., whether an athlete uses banned substances
regularly) by fitting a logistic curve to a predictor vari-
able [35]. Model fit was estimated using Akaike informa-
tion criterion (AIC), defined as 2k - 2ln (L),w h e r eL is
the likelihood for an estimated model with k parameters.
Thus the AIC is not testing the model with a traditional
null hypothesis but rather, it affords ranking and com-
paring competing statistical models taking complexity
into account. Statistical analyses were performed using
PASW Statistics 17 and R Statistical Computing.
Results
The mean age of the athletes in the sample (n = 86) was
23.07 (SD = 3.81; range 18-37; 53.5% female). The pre-
valence rates for self-reported nutritional supplement
and social drug use are presented in Table 2. Prevalence
Table 1 Expected domain specific FCE schema
Social projection (estimates)
Illicit (social) drug Performance enhancing drug Nutritional supplement
Illicit drug use Yes Higher than non-users’ estimate No difference No difference
No Lower than users’ estimate No difference No difference
Performance enhancing drug use Yes No difference Higher than non-users’ estimate No difference
No No difference Lower than users’ estimate No difference
Nutritional supplement use Yes No difference Ambiguous No difference
No No difference No difference
Table 2 Self reported illicit drug and nutritional
supplement use in the sample (no doping use was
reported)
Illicit drug
only
Supplements
only
Both None Total
Student-
athletes
24 17 13 32 86
Students
a 12 12 2 19 45
Total 36 29 15 51 131
a 14 missing.
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are presented for comparison. Only about one-third (27/
86) of the athletes believed that most people need sup-
plementation to balance their diet and 69/86 believed
that winning without doping is possible even at a high
level. These views suggest that in athletes’ mind, supple-
menting with prohibited and/or acceptable ‘extras’ is not
necessary. Whilst the majority of the athletes thought
that prohibited performance enhancing substances are
effective (ranging from effective to very effective), half of
the respondents did not know if supplements are good
and healthy substitutes for prohibited performance
enhancements or not.
Among athletes who responded to the survey, 46 met
the criteria of sport participation 3
rd grade or above
(average age = 23.62, SD = 3.93; range 18-37; 60.0%
female; 1 missing). Self-reported supplement use (43.5%)
was below that reported by the only epidemiological
study on Australian supplement use (52.2%) [42]. Self-
reported illicit drug use (47.8%) exceeded Australian
general population lifetime use (38.1%) but was compar-
able to the illicit lifetime drug use in the 20-29 age
group (54.0%) [43]. Some respondents (21.7%) reported
using both supplements and illicit drugs, leading to four
groups: non-users; supplement only; illicit only; and
“both”. No respondent self-reported doping. The official
estimate of doping in Australia in 2009 was 1%; 23/2312
athletes in the Australian Registered Testing Pool were
placed on the Register of Findings for performance
enhancing substances in 2008-2009, excluding cannabi-
noids and administrative entries [44]. Aggregated life-
time prevalence estimates of use were approximately
normally distributed for supplements (range 10-70,
skewness = 0.07, kurtosis = -0.96), illicit drugs (range
10-99, skewness = -0.63, kurtosis = -0.35) and doping
(range 0-50, skewness = 1.37, kurtosis = 1.07).
Evidence supporting domain specificity was found
among self-admitted illicit drug users. The simple models
of fitted logistic regression curves predicting the prob-
ability of social drug use based on social drug use esti-
mate and doping use estimate are depicted in Figure 2.
The model based on self-reported illicit drug use and
illicit drug use estimate showed a good fit (AIC =
179.180, -logL = 175.180, df = 137, p < 0.001); whereas
the model for predicting doping use based on self-
admitted social drug use was unsatisfactory (AIC =
66.494, -logL = 62.494, df = 44, p = 0.276). In practical
terms, the model fit (or the lack of fit in the case of cross
drug type prediction) provides some evidence for domain
specificity. The social drug use estimations given by
those who admitted its use were congruent with the pre-
viously observed FCE and resulted in a well fitting pre-
diction model. On the contrary, social drug users’
estimation of doping use failed to show an acceptable
relationship between behaviour and estimation. Should
there be no distinction made in athletes’ minds about
these two classes of drugs (social drug and doping), we
w o u l de x p e c tt os e eg o o df i t t i n gm o d e l sa c r o s sa l lf o u r
possible combinations of doping use, drug use, doping
estimates and social drug use estimates.
As expected, differences in social projection by the
user groups, including mixed groups, reflected the
group characteristics. All groups overestimated popula-
tion and sample prevalence of illicit drug use. No statis-
tically distinct FCE emerged for supplement use. Means,
standard deviations and ANOVA test statistics with cor-
responding p-values are presented in Table 3. Using the
four “user” groups, the FCE was statistically demon-
strated for illicit drug use, where post-hoc testing
revealed the illicit only group overestimated prevalence
relative to the non-user group. Supplement only users
reflected non-users, and the “both” group sat between
the other groups. Supplement only users appeared to
realistically gauge supplement use, at least within the
sample, with other groups underestimating. Illicit only
users underestimated by the greatest degree, followed by
“both” and non-users. No statistically distinct FCE
emerged for doping estimates. Supplement users esti-
mated doping 8-12 points less than all other groups.
The “both” group overestimated to the greatest degree,
with non-users and illicit only users offering similar
average estimates. All groups overestimated the official
population prevalence.
In terms of assessing the behavioural domain for dop-
ing, the results are ambiguous. Overestimation of doping
by non-users suggests something other than substance
u s ed r o v et h ee s t i m a t i o n .T h e relative underestimation
(although well above official estimates) by supplement
users supports this notion. The pattern of doping esti-
mation approximates that of illicit drugs with all groups
overestimating prevalence. This pattern fails to provide
firm evidence whether doping is related or unrelated to
other substance use behaviours.
Discussion
The FCE was found for illicit substance use and was evi-
dent as a trend for ergogenic supplement use. It is
unclear whether the results point to a relationship
between doping and either or neither of the other sub-
stances. The results associated with respondents who
used supplements suggested that doping estimates may
be influenced by ergogenic supplement use. Individuals
who used supplements tend to inflate the percentage of
individuals who dope but to a much smaller degree than
those who use other substances. In addition to these
main results, illicit drug use and doping were overesti-
mated. This indicates that, self-report notwithstanding;
Australian university athletes may have unrealistic
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the pilot nature of this study, especially the small sam-
ple, curtails generalisability. The results are therefore
interpreted under a generalisability caveat and are
intended to inform the broader research program with
regard to the observed trends.
The presence of the FCE within rather than between
substances provides an indication that nutritional sup-
plement use and illicit drug use come from different
behavioural domains. Individuals who admitted using
one particular type of drug tend to inflate the percen-
tage of individuals who uses the same drug to a much
larger degree than those who use other substances. This
suggests the FCE could provide an expedient way of
identifying when interventions designed to influence one
behaviour could influence another. The results indicate
that interventions aimed at illicit drug use are unlikely
to have much effect on supplement use, and vice versa.
Estimates of those who used both supplements and
illicit drugs were more akin to illicit drug users, suggest-
ing illicit drug use may be a dominant behavioural
domain. As Table 3 shows, users of ‘both’ illicit drugs
and NS gave similar social projections (67%) for illicit
drug use to the projected figure of those who use illicit
drugs only (74%), compared to a definitely lower esti-
mate (55%) given by NS-only users, suggesting that
users of ‘both’ may have behaved like illicit drug users
due to that domain requiring a different psychological
mechanism. For example, users of both may do so as a
function of substance use, whereas supplement only
users may do so for ergogenic reasons. The dominance
of illicit drug use may have implications for the domain
specificity of doping behaviour. A reversed pattern was
observed for NS use projection, where NS-only users
gave higher estimation (46%) compared to those who
use both (34%), thus providing further evidence that in
mixed behavioural categories, and the self-anchored
behavioural domain is context specific.
The effort to determine whether doping was more
akin to illicit drug or ergogenic supplement use led to
mixed results. Out of these mixed results, the marked
l o w e re s t i m a t eb ys u p p l e m e n tu s e r sm a yb eac l u e .
Mazanov et al [13] showed that elite athlete supplement
users were more knowledgeable about anti-doping rules
and procedures than non-users. Extrapolating this
observation to prevalence, athlete supplement users may
be more knowledgeable about prevalence rates com-
pared to those who have no contact with ergogenic sub-
stances. The other estimates imply that illicit drug users
(including the ‘both’ group) are as ignorant as non-users
Figure 2 Prediction model fit within (A) and outside (B) domain of illicit drugs.
Table 3 Illicit drug, supplement and doping estimates by
illicit and supplement drug use
Substance User Status n Mean SD F p
Illicit Drug Non-User 14 50.71 19.20 3.55 <0.03
Illicit Only 12 74.08 17.30
Supplement Only 10 55.20 23.56
Both 10 67.50 20.58
Supplement Non-User 14 38.21 13.39 2.23 >0.09
Illicit Only 12 30.00 14.30
Supplement Only 10 46.30 18.05
Both 10 34.50 15.36
Doping Non-User 14 13.57 11.00 1.49 >0.23
Illicit Only 12 12.25 15.45
Supplement Only 10 4.50 3.75
Both 10 16.10 17.82
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between knowledge of doping and the anti-doping
approach suggesting that doping is an ergogenic rather
than a substance use phenomenon needs to be tested.
The observation that the sample overestimated illicit
drug and doping use is concerning. Such overestimation
has been observed elsewhere [45] and represents a
potential normative misperception among tertiary level
students. The danger comes with such misperception
being identified as a predictor of drug use [36,37],
potentially increasing the likelihood of illicit drug use or
doping. The misperception may reflect a bias in the
overestimation of rare events [46,47]. While 38.1% of
Australians report lifetime use, the proportion of users
over different periods means illicit drug use is a rela-
tively rare behaviour: 5.1% in the last week, 7.7% in the
last month, 13.1% in the last 12 months [43]. Rarity is
even more significant for doping given the low official
rate. This issue could be assessed by calibrating FCE
studies against behaviours with different prevalence
rates, such as universal, common, uncommon and rare.
The result also underscores the need to generate realis-
tic norms around illicit drug use and doping use among
university student athletes.
The sample sizes themselves are a clear indication of
the low statistical power. In this instance, the statistical
tool is used to establish direction for future research
rather than establish definitive results that require a
higher level of statistical integrity. The intention of this
short report was to draw researchers’ and policy makers’
attention to this potentially important aspect of doping
behaviour to facilitate further targeted research. Future
research building on this pilot study should involve col-
lecting data from a representative larger sample that
delivers statistical certainty. Assessing knowledge of
doping and anti-doping to determine if it impacts dop-
ing estimates would strengthen the findings.
Conclusions
This pilot study provided an indication that harnessing
t h eF C Em i g h tb eaf r u i t f u la v e n u et of u r t h e re x a m i n e
whether doping behaviour has more in common with illi-
cit drug use or ergogenic supplement use. The pilot nat-
ure of the study suggests that doping may be an
ergogenic phenomenon, however further testing with an
improved research design and sample is needed to estab-
lish any such claim. The importance of having a precise
picture of the mental representation of doping is under-
scored by the increasing need for effective anti-doping
prevention and intervention. Further research is required
to establish if some athletes project their own behavioural
tendencies or actual behavior onto other athletes and
assume that many others feel or do the same and indeed
are using prohibited performance enhancing substances.
As a consequence, their own doping tendency or beha-
viour appears normal and normative, so that they can fol-
low it without compromising their own self-esteem and
social acceptance. In this vein, FCE has importance
beyond being a useful vector to understanding the posi-
tion of doping in athletes’ minds. These considerations,
coupled with the mental representation of doping in ath-
letes’ minds, suggest possible intervention strategies to
increase compliance with anti-doping initiatives.
Acknowledgements
The authors thank the university administrators who enabled the data
collection, and the student athletes who generously took part. We also
thank Dr Tamás Nepusz for producing the prediction models depicted in
Figure 2.
Author details
1School of Life Sciences, Kingston University, Penrhyn Road, Kingston upon
Thames, KT1 2EE, UK.
2Department of Psychology, The University of Sheffield,
Western Bank, Sheffield, S10 2TN, UK.
3School of Business, UNSW@ADFA,
Northcott Drive, Canberra ACT 2600, Australia.
Authors’ contributions
AP drafted and finalised the paper, and with DPN designed the study and
the questionnaire. JM collected and analysed the data, and developed early
drafts. All authors approved the final version the paper.
Competing interests
The authors declare that they have no competing interests.
Received: 22 October 2010 Accepted: 20 May 2011
Published: 20 May 2011
References
1. Mazanov J, Huybers T: An empirical model of athlete decisions to use
performance enhancing drugs: qualitative evidence. Qual Res Sport Exerc
2010, 2:385-402.
2. Lentillon-Kaestner V, Hagger MS, Hardcastle S: Health and doping in elite-
level cycling. Scand J Med Sci Sports 2011.
3. Strelan P, Boeckmann RJ: Why drug testing in elite sport does not work:
perceptual deterrence theory and the role of personal moral beliefs. J
Appl Soc Psycho 2006, 36:2909-2934.
4. Maycock B, Howat P: The barriers to illegal anabolic steroid use. Drugs
Educ Prev Policy 2005, 12:317-325.
5. DuRant RH, Answorth CS, Newman C, Rickert VI: Stability of the
relationships between anabolic steroid use and multiple substance use
among adolescents. J Adol Health 1994, 15:111-116.
6. DuRant RH, Escobedo LG, Heath GW: Anabolic-steroid use, strength
training, and multiple drug use among adolescents in the United States.
Pediatrics 1995, 96:23-28.
7. DuRant RH, Middleman AB, Faulkner AH, Emans SJ, Woods ER: Adolescent
anabolic-androgenic steroid use, multiple drug use, and high school
sports participation. Pediatric Exerc Sci 1997, 9:150-158.
8. DuRant RH, Rickert VI, Answorth CS, Newman C, Slavens G: Use of multiple
drugs among adolescents who use anabolic steroids. New Engl J Med
1993, 328:922-926.
9. Wanjek B, Rosendahl J, Strauss B, Gabriel HH: Doping, drugs and drug
abuse among adolescents in the State of Thuringia (Germany):
prevalence, knowledge and attitudes. Int J Sports Med 2007, 28:346-353.
10. Lisha NE, Sussman S: Relationship of high school and college sports
participation with alcohol, tobacco, and illicit drug use: a review.
Addictive Behav 2010, 35:399-407.
11. Petróczi A, Aidman EV: Psychological drivers in doping: the life-cycle model
of performance enhancement. Subst Abuse Treatmeny Prev Policy 2008, 3:7.
12. Papadopoulos FC, Skalkidis I, Parkkari J, Petridou E, “Sports Injuries”
European Union Group: Doping use among tertiary education students in
six developed countries. Eur J Epidemiol 2006, 21:307-313.
Petróczi et al. Substance Abuse Treatment, Prevention, and Policy 2011, 6:10
http://www.substanceabusepolicy.com/content/6/1/10
Page 7 of 813. Mazanov J, Petróczi A, Bingham J, Holloway A: Towards an empirical
model of performance enhancing supplement use: a pilot study among
high performance UK athletes. J Sci Med Sport 2009, 11:185-190.
14. Lentillon-Kaestner V, Carstairs C: Doping use among elite cyclists: a
qualitative psychosociological approach. Scand J Med Sci Sports 2010,
20:336-345.
15. Smith ACT, Stewart B, Oliver-Bennetts S, McDonald S, Ingerson L,
Anderson A, Dickson G, Emery P, Graetz F: Contextual influences and
athlete attitudes to drugs in sport. Sport Management Review 2010.
16. Hardie M, Shilbury M, Ware I, Bozzi C: I wish I was twenty-one now.
Beyond doping in the Australian Peloton. Research report [http://www.
newcyclingpathway.com/wp-content/uploads/2010/09/21-NOW-FINAL-.pdf].
17. Christiansen AV: “We are not sportsmen, we are professionals":
professionalism, doping and deviance in elite sport. Int J Sp Management
Marketing 2010, 7:91-103.
18. Bloodworth A, McNamee M: Clean Olympians? Doping and anti-doping:
the views of talented young British athletes. Int J Drug Policy 2010,
21:276-282.
19. Mazanov J, Huybers T, Connor J: Qualitative evidence of a primary
intervention point for elite athlete doping. J Sci Med Sport 2010,
14:106-110.
20. Perko M, Bartee R, Dunn M, Wang M, Eddy JM: Giving new meaning to
the term “taking one for the team": influences on the use/non-use of
dietary supplements among adolescent athletes. Am J Health Studies
2000, 16:99-106.
21. Taioli E: Use of permitted drugs in Italian professional soccer players. Br J
Sp Med 2007, 41:439-441.
22. Tscholl P, Alonso JM, Dolle G, Junge A, Dvorak J: The use of drugs and
nutritional supplements in top-level track and field athletes. Am J Sp
Med 2010, 38:133-140.
23. Tscholl P, Junge A, Dvorak J: The use of medication and nutritional
supplements during FIFA World Cups 2002 and 2006. Br J Sp Med 2008,
42:725-730.
24. Tsitsimpikou C, Jamurtas A, Fitch K, Papalexis P, Tsarouhas K: Medication
use by athletes during the Athens 2004 Paralympic Games. Br J Sp Med
2009, 43:1062-1066.
25. Tsitsimpikou C, Tsiokanos A, Tsarouhas K, Schamasch P, Fitch KD,
Valasiadis D, Jamurtas A: Medication use by athletes at the Athens 2004
Summer Olympic Games. Clin J Sp Med 2009, 19:33-38.
26. Nieper A: Nutritional supplement practices in UK junior track and field
athletes. Br J Sp Med 2005, 39:645-649.
27. Erdman KA, Fung TS, Doyle-Barker PK, Verhoef MJ, Reimer RA: Dietary
supplementation of high-performance Canadian athletes by age and
gender. Clin J Sport Med 2007, 17:458-464.
28. Petroczi A, Naughton DP: The age-gender-status profile of high
performing athletes in the UK taking nutritional supplements: lessons
for the future. J Int Soc Sp Nutr 2008, 5:2.
29. Petroczi A, Naughton DP, Pearce G, Bloodworth A, Bailey R, McNamee M:
Nutritional supplement use by elite young UK athletes: fallacies of
advice regarding efficacy. J Int Soc Sp Nutr 2008, 5:22.
30. Petroczi A, Naughton DP, Mazanov J, Holloway A, Bingham J: Performance
enhancement with supplements: incongruence between rationale and
practice. J Int Soc Sp Nutr 2007, 4:19.
31. Suzic Lazic J, Dikic N, Radivojevic N, Mazic S, Radovanovic D, Mitrovic N,
Lazic M, Zivanic S, Suzic S: Dietary supplements and medications in elite
sport - polypharmacy or real need? Scand J Med Sci Sports 2009,
21:260-267.
32. Petroczi A, Naughton DP: Potentially fatal trend in performance
enhancement: a cautionary note on nitrite. J Int Soc Sp Nutr 2010, 7:25.
33. Dunn M, Mazanov J, Sithartan G: Predicting future anabolic-androgenic
steroid use intentions with current substance use: findings from an
Internet-based survey. Clin J Sports Med 2009, 19:222-227.
34. Petróczi A, Mazanov J, Nepusz T, Backhouse SH, Naughton DP: Comfort in
big numbers: Does over-estimation of doping prevalence in others
indicate self-involvement? J Occupational Med Toxic 2008, 3:19.
35. Uvacsek M, Ránky M, Nepusz T, Naughton DP, Mazanov J, Petróczi A: Self-
admitted behaviour and perceived use of performance enhancing
versus psychoactive drugs among competitive athletes. Scand J Sci Med
Sport 2011, 21:224-234.
36. Petróczi A, Aidman EV, Hussain I, Deshmukh N, Nepusz T, Uvacsek M,
Tóth M, Barker J, Naughton DP: Virtue or pretense? Looking behind self-
declared innocence in doping. PLoS One 2010, 5(5):e10457.
37. Petróczi A, Uvacsek M, Nepusz T, Deshmukh N, Shah I, Aidman EV, Barker J,
Tóth M, Naughton DP: Incongruence in doping related attitudes, beliefs
and opinions in the context of discordant behavioural data: in which
measure do we trust? PLoS One 2011, 6(4):e18804.
38. Petroczi A, Uvacsek M, Nepusz T, Naughton D: Initiator or consequence:
the relationship between perceived use of doping by others and
behaviour. J Sci Med Sport 2010, 12:e1-e232.
39. Ross L, Greene D, House P: The false consensus effect: an egocentric bias
in social perception and attribution processes. J Exp Social Psychol 1977,
13:279-301.
40. LaBrie JW, Grossbard JR, Hummer JF: Normative misperceptions and
marijuana use among male and female college athletes. J Appl Sport
Psychol 2009, 21(Supp 1):S77-S85.
41. Suls J, Wan CK, Sanders GS: False consensus and false uniqueness in
estimating the prevalence of health-protective behaviours. J Appl Social
Psychol 1988, 18:66-79.
42. MacLennan AH, Myers SP, Taylor AW: The continuing use of
complementary and alternative medicine in South Australia: costs and
beliefs in 2004. Med J Australia 2006, 184:27-31.
43. AIHW: 2007 National Drug Strategy Household Survey: Detailed Findings. Drug
Statistics Series, No. 22 Canberra: Australian Institute of Health & Welfare;
2008, 38-39.
44. ASADA: 2008-09 Annual Report Canberra, Australian Sports Anti-Doping
Authority; 2009, 117.
45. Page RM, Roland M: Misperceptions of the prevalence of marijuana use
among college students: athletes and non-athletes. J Child Adol Subs
Abuse 2004, 14:61-75.
46. Weinstein ND: Perceived probability, perceived severity, and health-
protective behaviour. Health Psychol 2000, 19:65-74.
47. Wickens CD, Hollands JG: Engineering Psychology and Human Performance. 3
edition. Upper Saddle River, NJ: Prentice Hall; 2000, 293-324.
doi:10.1186/1747-597X-6-10
Cite this article as: Petróczi et al.: Inside athletes’ minds: Preliminary
results from a pilot study on mental representation of doping and
potential implications for anti-doping. Substance Abuse Treatment,
Prevention, and Policy 2011 6:10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Petróczi et al. Substance Abuse Treatment, Prevention, and Policy 2011, 6:10
http://www.substanceabusepolicy.com/content/6/1/10
Page 8 of 8